133 related articles for article (PubMed ID: 7960982)
41. Curative radiotherapy for laparotomy-staged IA, IIA, IIIA Hodgkin's disease: an evaluation of the gains achieved with radical radiotherapy.
Lee CK; Aeppli DM; Bloomfield CD; Levitt SH
Int J Radiat Oncol Biol Phys; 1990 Sep; 19(3):547-59. PubMed ID: 2211203
[TBL] [Abstract][Full Text] [Related]
42. A multivariate analysis of prognostic factors in early stage Hodgkin's disease.
Tubiana M; Henry-Amar M; van der Werf-Messing B; Henry J; Abbatucci J; Burgers M; Hayat M; Somers R; Laugier A; Carde P
Int J Radiat Oncol Biol Phys; 1985 Jan; 11(1):23-30. PubMed ID: 3881375
[TBL] [Abstract][Full Text] [Related]
43. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.
Longo DL; Duffey PL; Young RC; Hubbard SM; Ihde DC; Glatstein E; Phares JC; Jaffe ES; Urba WJ; DeVita VT
J Clin Oncol; 1992 Feb; 10(2):210-8. PubMed ID: 1732422
[TBL] [Abstract][Full Text] [Related]
44. Clinical versus pathologic stage I and II Hodgkin's disease.
Cox JD; Stoffel TJ
Oncology; 1980; 37(5):325-8. PubMed ID: 7443165
[TBL] [Abstract][Full Text] [Related]
45. Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy.
Brusamolino E; Lazzarino M; Orlandi E; Canevari A; Morra E; Castelli G; Alessandrino EP; Pagnucco G; Astori C; Livraghi A
Ann Oncol; 1994; 5 Suppl 2():101-6. PubMed ID: 7515642
[TBL] [Abstract][Full Text] [Related]
46. [Hodgkin's disease: the value of prognostic criteria and of the combination of radiotherapy and chemotherapy in localised lymphoid stages (I and II). 94 patients undergoing laparotomy (author's transl)].
Bernadou A; Blanc CM; James JM; Dao C; Zittoun R; Bilski-Pasquier G
Nouv Presse Med; 1978 Mar; 7(10):807-12. PubMed ID: 643545
[TBL] [Abstract][Full Text] [Related]
47. The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience.
Hoppe RT; Coleman CN; Cox RS; Rosenberg SA; Kaplan HS
Blood; 1982 Mar; 59(3):455-65. PubMed ID: 7059665
[TBL] [Abstract][Full Text] [Related]
48. NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease.
Hagemeister FB; Cabanillas F; Velásquez WS; Meistrich ML; Liang JC; McLaughlin P; Redman JR; Romaguera JE; Rodríguez MA; Swan F
Semin Oncol; 1990 Dec; 17(6 Suppl 10):34-8; discussion 38-40. PubMed ID: 2259922
[TBL] [Abstract][Full Text] [Related]
49. Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin's disease.
Mauch P; Gorshein D; Cunningham J; Hellman S
Cancer Treat Rep; 1982 Apr; 66(4):809-17. PubMed ID: 7074652
[TBL] [Abstract][Full Text] [Related]
50. Prognostic factors in patients with subdiaphragmatic Hodgkin's disease.
Mauch P; Greenberg H; Lewin A; Cassady JR; Weichselbaum R; Hellman S
Hematol Oncol; 1983; 1(3):205-14. PubMed ID: 6677563
[TBL] [Abstract][Full Text] [Related]
51. The place of radiotherapy in the management of localised Hodgkin's disease (Report no 11).
Hope-Stone HF
Clin Radiol; 1981 Sep; 32(5):519-22. PubMed ID: 7273645
[TBL] [Abstract][Full Text] [Related]
52. Prognostic factors in Hodgkin's disease stage IV.
Specht L; Nissen NI
Eur J Haematol; 1988 Oct; 41(4):359-67. PubMed ID: 3197822
[TBL] [Abstract][Full Text] [Related]
53. Prognostic influence of early diagnostic splenectomy in Hodgkin's disease. A long-term follow-up.
Askergren J; Björkholm M; Holm G; Johansson B; Mellstedt H
Acta Med Scand; 1986; 219(3):315-22. PubMed ID: 3518342
[TBL] [Abstract][Full Text] [Related]
54. [Treatment results of Hodgkin's disease, stages I and II (author's transl)].
Gassmann W; Pralle H; Löffler H; Gluth-Stender M
Klin Wochenschr; 1981 May; 59(10):469-75. PubMed ID: 7241947
[TBL] [Abstract][Full Text] [Related]
55. Lymphocyte predominant Hodgkin's disease: clinical presentation and results of treatment.
Russell KJ; Hoppe RT; Colby TV; Burns BF; Cox RS; Kaplan HS
Radiother Oncol; 1984 Jan; 1(3):197-205. PubMed ID: 6505256
[TBL] [Abstract][Full Text] [Related]
56. Salvage radiotherapy following chemotherapy failure in Hodgkin's disease--what is its role?
O'Brien PC; Parnis FX
Acta Oncol; 1995; 34(1):99-104. PubMed ID: 7865243
[TBL] [Abstract][Full Text] [Related]
57. Mantel irradiation for stage I and stage II Hodgkin's disease--results of a 10 year experience.
Liew KH; Ding JC; Matthews JP; Ironside PJ; Beadle GF; Cooper IA; Madigan JP; Parkin FG
Aust N Z J Med; 1983 Apr; 13(2):135-40. PubMed ID: 6577832
[TBL] [Abstract][Full Text] [Related]
58. Patterns of relapse following radiotherapy for Hodgkin's disease.
Yarnold JR; Jelliffe AM; Hudson GV
Clin Radiol; 1982 Mar; 33(2):137-40. PubMed ID: 6978226
[TBL] [Abstract][Full Text] [Related]
59. Five-year results of the E.O.R.T.C. randomized study of splenectomy and spleen irradiation in clinical stages I and II of Hodgkin's disease.
Tubiana M; Hayat M; Henry-Amar M; Breur K; van der Werf Messing B; Burgers M
Eur J Cancer (1965); 1981 Mar; 17(3):355-63. PubMed ID: 7021162
[No Abstract] [Full Text] [Related]
60. Mantle field irradiation for stages IA and IIA Hodgkin's disease.
Abrahamsen AF; Høst H
Scand J Haematol; 1981 Apr; 26(4):306-10. PubMed ID: 7336146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
